Date: 2011-06-23
Type of information: Grant
Company: Scil Technology (Germany)
Investors: Federal Ministry of Education and Research (BMBF)(Germany)
Amount: € 0.9 million
Funding type: grant
Planned used: The € 0.9 million grant supports Scil Technology’s research program to explore the therapeutic potential of repellent proteins for the treatment of rheumatoid arthritis.
Others:
Therapeutic area: Autoimmune diseases – Inflammatory diseases - Rheumatic diseases
